118 related articles for article (PubMed ID: 38871281)
1. A nationwide cohort study of Delta and Omicron SARS-CoV-2 outcomes in vaccinated individuals with chronic lung disease.
Wee LE; Tan JYJ; Chiew CJ; Abisheganaden JA; Chotirmall SH; Lye DCB; Tan KB
Chest; 2024 Jun; ():. PubMed ID: 38871281
[TBL] [Abstract][Full Text] [Related]
2. Vaccine effectiveness against SARS-CoV-2 infection or COVID-19 hospitalization with the Alpha, Delta, or Omicron SARS-CoV-2 variant: A nationwide Danish cohort study.
Gram MA; Emborg HD; Schelde AB; Friis NU; Nielsen KF; Moustsen-Helms IR; Legarth R; Lam JUH; Chaine M; Malik AZ; Rasmussen M; Fonager J; Sieber RN; Stegger M; Ethelberg S; Valentiner-Branth P; Hansen CH
PLoS Med; 2022 Sep; 19(9):e1003992. PubMed ID: 36048766
[TBL] [Abstract][Full Text] [Related]
3. Long-term neuropsychiatric sequelae of Delta versus Omicron SARS-CoV-2 infection.
Wee LE; Lim JT; Tay AT; Pang D; Dickens B; Chiew CJ; Ong B; Lye DCB; Tan KB
Clin Microbiol Infect; 2024 Apr; 30(4):531-539. PubMed ID: 38141822
[TBL] [Abstract][Full Text] [Related]
4. A Quick Displacement of the SARS-CoV-2 variant Delta with Omicron: Unprecedented Spike in COVID-19 Cases Associated with Fewer Admissions and Comparable Upper Respiratory Viral Loads.
Fall A; Eldesouki RE; Sachithanandham J; Morris CP; Norton JM; Gaston DC; Forman M; Abdullah O; Gallagher N; Li M; Swanson NJ; Pekosz A; Klein EY; Mostafa HH
medRxiv; 2022 Jan; ():. PubMed ID: 35118480
[TBL] [Abstract][Full Text] [Related]
5. Risk and symptoms of COVID-19 in health professionals according to baseline immune status and booster vaccination during the Delta and Omicron waves in Switzerland-A multicentre cohort study.
Babouee Flury B; Güsewell S; Egger T; Leal O; Brucher A; Lemmenmeier E; Meier Kleeb D; Möller JC; Rieder P; Rütti M; Schmid HR; Stocker R; Vuichard-Gysin D; Wiggli B; Besold U; McGeer A; Risch L; Friedl A; Schlegel M; Kuster SP; Kahlert CR; Kohler P;
PLoS Med; 2022 Nov; 19(11):e1004125. PubMed ID: 36342956
[TBL] [Abstract][Full Text] [Related]
6. Severe hospital events following symptomatic infection with Sars-CoV-2 Omicron and Delta variants in France, December 2021-January 2022: A retrospective, population-based, matched cohort study.
Auvigne V; Vaux S; Strat YL; Schaeffer J; Fournier L; Tamandjou C; Montagnat C; Coignard B; Levy-Bruhl D; Parent du Châtelet I
EClinicalMedicine; 2022 Jun; 48():101455. PubMed ID: 35611065
[TBL] [Abstract][Full Text] [Related]
7. Real-world effectiveness of nirmatrelvir/ritonavir against COVID-19 hospitalizations and severe COVID-19 in community-dwelling elderly Singaporeans during Omicron BA.2, BA.4/5, and XBB transmission.
Wee LE; Tay AT; Chiew C; Young BE; Wong B; Lim R; Lee CL; Tan J; Vasoo S; Lye DC; Tan KB
Clin Microbiol Infect; 2023 Oct; 29(10):1328-1333. PubMed ID: 37331509
[TBL] [Abstract][Full Text] [Related]
8. Risk of severe clinical outcomes among persons with SARS-CoV-2 infection with differing levels of vaccination during widespread Omicron (B.1.1.529) and Delta (B.1.617.2) variant circulation in Northern California: A retrospective cohort study.
Skarbinski J; Wood MS; Chervo TC; Schapiro JM; Elkin EP; Valice E; Amsden LB; Hsiao C; Quesenberry C; Corley DA; Kushi LH
Lancet Reg Health Am; 2022 Aug; 12():100297. PubMed ID: 35756977
[TBL] [Abstract][Full Text] [Related]
9. Clinical progression, disease severity, and mortality among adults hospitalized with COVID-19 caused by the Omicron and Delta SARS-CoV-2 variants: A population-based, matched cohort study.
COVID-19 Omicron Delta study group
PLoS One; 2023; 18(4):e0282806. PubMed ID: 37104488
[TBL] [Abstract][Full Text] [Related]
10. Clinical Characteristics and Outcomes Among Adults Hospitalized with Laboratory-Confirmed SARS-CoV-2 Infection During Periods of B.1.617.2 (Delta) and B.1.1.529 (Omicron) Variant Predominance - One Hospital, California, July 15-September 23, 2021, and December 21, 2021-January 27, 2022.
Modes ME; Directo MP; Melgar M; Johnson LR; Yang H; Chaudhary P; Bartolini S; Kho N; Noble PW; Isonaka S; Chen P
MMWR Morb Mortal Wkly Rep; 2022 Feb; 71(6):217-223. PubMed ID: 35143466
[TBL] [Abstract][Full Text] [Related]
11. Vaccine effectiveness against SARS-CoV-2 reinfection during periods of Alpha, Delta, or Omicron dominance: A Danish nationwide study.
Nielsen KF; Moustsen-Helms IR; Schelde AB; Gram MA; Emborg HD; Nielsen J; Hansen CH; Andersen MA; Meaidi M; Wohlfahrt J; Valentiner-Branth P
PLoS Med; 2022 Nov; 19(11):e1004037. PubMed ID: 36413551
[TBL] [Abstract][Full Text] [Related]
12. Comparative analysis of the risks of hospitalisation and death associated with SARS-CoV-2 omicron (B.1.1.529) and delta (B.1.617.2) variants in England: a cohort study.
Nyberg T; Ferguson NM; Nash SG; Webster HH; Flaxman S; Andrews N; Hinsley W; Bernal JL; Kall M; Bhatt S; Blomquist P; Zaidi A; Volz E; Aziz NA; Harman K; Funk S; Abbott S; ; Hope R; Charlett A; Chand M; Ghani AC; Seaman SR; Dabrera G; De Angelis D; Presanis AM; Thelwall S
Lancet; 2022 Apr; 399(10332):1303-1312. PubMed ID: 35305296
[TBL] [Abstract][Full Text] [Related]
13. Immune responses in COVID-19 patients during breakthrough infection with SARS-CoV-2 variants Delta, Omicron-BA.1 and Omicron-BA.5.
Bormann M; Brochhagen L; Alt M; Otte M; Thümmler L; van de Sand L; Kraiselburd I; Thomas A; Gosch J; Braß P; Ciesek S; Widera M; Dolff S; Dittmer U; Witzke O; Meyer F; Lindemann M; Schönfeld A; Rohn H; Krawczyk A
Front Immunol; 2023; 14():1150667. PubMed ID: 37520539
[TBL] [Abstract][Full Text] [Related]
14. Risks of SARS-CoV-2 JN.1 infection and COVID-19 associated emergency-department (ED) visits/hospitalizations following updated boosters and prior infection: a population-based cohort study.
Chong C; Wee LE; Jin X; Zhang M; Malek MIA; Ong B; Lye D; Chiew CJ; Tan KB
Clin Infect Dis; 2024 Jun; ():. PubMed ID: 38922669
[TBL] [Abstract][Full Text] [Related]
15. Estimated Effectiveness of COVID-19 Vaccines Against Omicron or Delta Symptomatic Infection and Severe Outcomes.
Buchan SA; Chung H; Brown KA; Austin PC; Fell DB; Gubbay JB; Nasreen S; Schwartz KL; Sundaram ME; Tadrous M; Wilson K; Wilson SE; Kwong JC
JAMA Netw Open; 2022 Sep; 5(9):e2232760. PubMed ID: 36136332
[TBL] [Abstract][Full Text] [Related]
16. The displacement of the SARS-CoV-2 variant Delta with Omicron: An investigation of hospital admissions and upper respiratory viral loads.
Fall A; Eldesouki RE; Sachithanandham J; Morris CP; Norton JM; Gaston DC; Forman M; Abdullah O; Gallagher N; Li M; Swanson NJ; Pekosz A; Klein EY; Mostafa HH
EBioMedicine; 2022 May; 79():104008. PubMed ID: 35460989
[TBL] [Abstract][Full Text] [Related]
17. SARS-CoV-2 infection following booster vaccination: Illness and symptom profile in a prospective, observational community-based case-control study.
Antonelli M; Penfold RS; Canas LDS; Sudre C; Rjoob K; Murray B; Molteni E; Kerfoot E; Cheetham N; Pujol JC; Polidori L; May A; Wolf J; Modat M; Spector T; Hammers A; Ourselin S; Steves C
J Infect; 2023 Dec; 87(6):506-515. PubMed ID: 37777159
[TBL] [Abstract][Full Text] [Related]
18. Outcomes of the SARS-CoV-2 omicron (B.1.1.529) variant outbreak among vaccinated and unvaccinated patients with cancer in Europe: results from the retrospective, multicentre, OnCovid registry study.
Pinato DJ; Aguilar-Company J; Ferrante D; Hanbury G; Bower M; Salazar R; Mirallas O; Sureda A; Plaja A; Cucurull M; Mesia R; Townsend S; Jackson A; Dalla Pria A; Newsom-Davis T; Handford J; Sita-Lumsden A; Apthorp E; Vincenzi B; Bertuzzi A; Brunet J; Lambertini M; Maluquer C; Pedrazzoli P; Biello F; Sinclair A; Bawany S; Khalique S; Rossi S; Rogers L; Murphy C; Belessiotis K; Carmona-García MC; Sharkey R; García-Illescas D; Rizzo G; Perachino M; Saoudi-Gonzalez N; Doonga K; Fox L; Roldán E; Gaidano G; Ruiz-Camps I; Bruna R; Patriarca A; Martinez-Vila C; Cantini L; Zambelli A; Giusti R; Mazzoni F; Caliman E; Santoro A; Grosso F; Parisi A; Queirolo P; Aujayeb A; Rimassa L; Prat A; Tucci M; Libertini M; Grisanti S; Mukherjee U; Diamantis N; Fusco V; Generali D; Provenzano S; Gennari A; Tabernero J; Cortellini A;
Lancet Oncol; 2022 Jul; 23(7):865-875. PubMed ID: 35660139
[TBL] [Abstract][Full Text] [Related]
19. Likelihood of infecting or getting infected with COVID-19 as a function of vaccination status, as investigated with a stochastic model for Aotearoa New Zealand for Delta and Omicron variants.
Watson LM
N Z Med J; 2022 Apr; 135():89-100. PubMed ID: 35728188
[TBL] [Abstract][Full Text] [Related]
20. SARS-CoV-2 Infection and Hospitalization Among Adults Aged ≥18 Years, by Vaccination Status, Before and During SARS-CoV-2 B.1.1.529 (Omicron) Variant Predominance - Los Angeles County, California, November 7, 2021-January 8, 2022.
Danza P; Koo TH; Haddix M; Fisher R; Traub E; OYong K; Balter S
MMWR Morb Mortal Wkly Rep; 2022 Feb; 71(5):177-181. PubMed ID: 35113851
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
